Faropenem sodiumFaropenem sodium
MedChemExpress (MCE)
HY-76260
122547-49-3
98.87%
-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Faropenem sodium is an orally bioavailable penem antibiotic. Faropenem sodium regulates inorganic phosphate transporter Npt1. Faropenem sodium inhibits M. tuberculosis (MIC of 1.3 μg/mL) and B. anthracis.
Faropenem (0.0015-200 μg/mL, 4-7 days) sodium exhibits antituberculosis activity against M. tuberculosis, with MIC of 1.3 μg/mL (with or without clavulanate)[1]. Faropenem (14C radiolabeled, 1 μCi/μL, 30 min) sodium transports across the renal epithelial luminal membrane via inorganic phosphate transporter Npt1[2].
Faropenem (500 mg/kg, p.o., from days 1 to 7 postinfection) sodium reduces bacterial (M. tuberculosis) load in an murine infection model of acute tuberculosis[1]. Faropenem (10-80 mg/kg/day, i.p., 24 h postchallenge at 4-, 6-, and 12-h intervals for 14 days) sodium demonstrates a high level of activity against B. anthracis in the murine postexposure prophylaxis inhalation model[3].
Bacterial[1] In Vitro Faropenem (0.0015-200 μg/mL, 4-7 days) sodium exhibits antituberculosis activity against M. tuberculosis, with MIC of 1.3 μg/mL (with or without clavulanate)[1]. Faropenem (14C radiolabeled, 1 μCi/μL, 30 min) sodium transports across the renal epithelial luminal membrane via inorganic phosphate transporter Npt1[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Faropenem sodium Related Antibodies
| | | |
| | | | | |
[1]. Dhar N, et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob Agents Chemother. 2015 Feb
59(2):1308-19. [Content Brief]
[2]. Uchino H, et al. Faropenem transport across the renal epithelial luminal membrane via inorganic phosphate transporter Npt1. Antimicrob Agents Chemother. 2000 Mar
44(3):574-7. [Content Brief]
[3]. Gill SC, et al. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. Antimicrob Agents Chemother. 2010 May
54(5):1678-83. [Content Brief]